G. Perrault

发表

Potentiation of prepulse inhibition of the startle reflex in rats: pharmacological evaluation of the procedure as a model for detecting antipsychotic activity

R. Depoortère, G. Perrault, D. Sanger, 1997, Psychopharmacology.

Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents

G. Perrault, G. Griebel, P. Soubrié, 2001, Psychopharmacology.

Repeated treatment with alpidem, a new anxiolytic, does not induce tolerance or physical dependence

G. Perrault, D. Sanger, B. Zivkovic, 1993, Neuropharmacology.

Animal models of anxiety and the development of novel anxiolytic drugs

G. Perrault, D. Sanger, B. Zivkovic, 1991, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Alpidem, an omega-1 receptor-selective partial agonist: a new approach to anxiety treatment

G. Perrault, D. Sanger, S. Z. Langer, 1991, European Neuropsychopharmacology.

Animal Models and Recent Developments in the Search for Novel Anxiolytics

G. Perrault, D. Sanger, B. Zivkovic, 1991 .

Differences in pharmacological profiles of a new generation of benzodiazepine and non-benzodiazepine hypnotics.

G. Perrault, D. Sanger, B. Zivkovic, 1990, European journal of pharmacology.

The interaction between zolpidem and beta-CMC: a clue to the identification of receptor sites involved in the sedative effect of zolpidem.

G. Perrault, D. Sanger, B. Zivkovic, 1988, European journal of pharmacology.

Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects.

G. Perrault, D. Sanger, K. Lloyd, 1986, The Journal of pharmacology and experimental therapeutics.

The D3 Antagonist PNU-99194A Potentiates the Discriminative Cue Produced by the D3 Agonist 7-OH-DPAT

R. Depoortère, G. Perrault, D. Sanger, 2000, Pharmacology Biochemistry and Behavior.

Effects of D1 dopamine receptor agonists on oral ethanol self-administration in rats: comparison with their efficacy to produce grooming and hyperactivity

G. Perrault, D. Sanger, C. Cohen, 1999, Psychopharmacology.

Preferential involvement of D3 versus D2 dopamine receptors in the effects of dopamine receptor ligands on oral ethanol self-administration in rats

G. Perrault, D. Sanger, C. Cohen, 1998, Psychopharmacology.

Pharmacological evidence for the involvement of sigma sites in DTG-induced contralateral circling in rats

G. Perrault, D. Sanger, S. Bastianetto, 1995, Neuropharmacology.

Effects of typical and atypical antipsychotic drugs on response decrement patterns in rats.

G. Perrault, D. Sanger, 1995, The Journal of pharmacology and experimental therapeutics.

In vivo pharmacological profile of SL 84.0418, a new selective, peripherally active alpha 2-adrenoceptor antagonist.

G. Perrault, H. Schoemaker, S. Z. Langer, 1993, European journal of pharmacology.

Evidence for the involvement of dopamine receptors in ethanol-induced hyperactivity in mice

G. Perrault, D. Sanger, C. Cohen, 1997, Neuropharmacology.

The mouse defense test battery: evaluation of the effects of non-selective and BZ-1 (omega1) selective, benzodiazepine receptor ligands.

G. Perrault, D. Sanger, G. Griebel, 1996, Behavioural pharmacology.

Comparison of the pharmacological properties of classical and novel BZ-omega receptor ligands.

G. Perrault, D. Sanger, H. Schoemaker, 1999, Behavioural pharmacology.

Intracranial self-stimulation under a progressive-ratio schedule in rats: effects of strength of stimulation, d-amphetamine, 7-OH-DPAT and haloperidol

R. Depoortère, G. Perrault, D. Sanger, 1999, Psychopharmacology.

The preclinical pharmacologic profile of tiapride

G. Perrault, D. Sanger, H. Schoemaker, 2001, European Psychiatry.

The Pharmacological Properties of Tiapride

G. Perrault, D. Sanger, H. Schoemaker, 1998 .

Reduction of Oral Ethanol Self-Administration in Rats by Monoamine Oxidase Inhibitors

G. Perrault, D. Sanger, C. Cohen, 1999, Pharmacology Biochemistry and Behavior.

SSR591813, a Novel Selective and Partial α4β2 Nicotinic Receptor Agonist with Potential as an Aid to Smoking Cessation

G. Perrault, P. Soubrié, O. Bergis, 2003, Journal of Pharmacology and Experimental Therapeutics.

SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation.

G. Perrault, P. Soubrié, O. Bergis, 2003, The Journal of pharmacology and experimental therapeutics.

SL651498: An Anxioselective Compound with Functional Selectivity for a 2 - and a 3 -Containing g -Aminobutyric Acid A (GABA A ) Receptors

G. Perrault, H. Schoemaker, G. Griebel, 2001 .

Subtype-selective benzodiazepine receptor ligands

G. Perrault, D. Sanger, G. Griebel, 2000 .

Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs

G. Perrault, D. Sanger, G. Griebel, 1997, Psychopharmacology.

Discriminative Stimulus Effects of Drugs Acting at GABAA Receptors Differential Profiles and Receptor Selectivity

G. Perrault, D. Sanger, H. Schoemaker, 1999, Pharmacology Biochemistry and Behavior.

SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats

G. Perrault, P. Soubrié, C. Cohen, 2002, Behavioural pharmacology.

Benzodiazepine (ω) receptor partial agonists and the acquisition of conditioned fear in mice

G. Perrault, D. Sanger, D. Joly, 1995, Psychopharmacology.

Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: Evidence for the functional significance of receptor subtypes

G. Perrault, D. Sanger, C. Cohen, 1994, Neuroscience & Biobehavioral Reviews.

Pharmacological and Behavioral Profile of Alpidem as an Anxiolytic

G. Perrault, D. Sanger, K. Lloyd, 1990, Pharmacopsychiatry.

The behavioral profile of zolpidem, a novel hypnotic drug of imidazopyridine structure

D. J. Sanger, E. Morel, G. Perrault, 1987, Physiology & Behavior.

Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents Comparison with diazepam and buspirone

G. Perrault, D. Sanger, G. Griebel, 1998, Psychopharmacology.

Neurochemical, Electrophysiological and Pharmacological Profiles of the Selective Inhibitor of the Glycine Transporter-1 SSR504734, a Potential New Type of Antipsychotic

R. Depoortère, G. Perrault, G. Griebel, 2005, Neuropsychopharmacology.

Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine–oxidase activity and monoamine levels

G. Perrault, D. Sanger, G. Griebel, 1998, Neuropharmacology.

DTG-induced circling behaviour in rats may involve the interaction between σ sites and nigro-striatal dopaminergic pathways

G. Perrault, D. Sanger, L. Rouquier, 1995, Neuropharmacology.

Pharmacological studies on synthetic flavonoids: comparison with diazepam

G. Perrault, D. Sanger, H. Schoemaker, 1999, Neuropharmacology.

Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice

G. Perrault, D. Sanger, G. Griebel, 2000, Psychopharmacology.

Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice.

R. Depoortère, G. Perrault, D. Sanger, 2000, European journal of pharmacology.

Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists

R. Depoortère, G. Perrault, D. Sanger, 1999, Neuropharmacology.

Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice

R. Depoortère, G. Perrault, D. Sanger, 1999, Neuropharmacology.

Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem.

G. Perrault, D. Sanger, E. Morel, 1996, European journal of pharmacology.

Discriminative stimulus effects of apomorphine and 7-OH-DPAT: a potential role for dopamine D3 receptors

R. Depoortère, G. Perrault, D. Sanger, 1997, Psychopharmacology.

Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.

D J Sanger, R. Depoortère, G. Perrault, 1997, The Journal of pharmacology and experimental therapeutics.

SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms.

G. Perrault, H. Schoemaker, G. Griebel, 2003, CNS drug reviews.

SL651498: An Anxioselective Compound with Functional Selectivity for α2- and α3-Containing γ-Aminobutyric AcidA (GABAA) Receptors

G. Perrault, H. Schoemaker, G. Griebel, 2001 .

Characterization of the discriminative stimulus produced by the dopamine antagonist tiapride.

G. Perrault, D. Sanger, C. Cohen, 1997, The Journal of pharmacology and experimental therapeutics.

Orphanin FQ, a novel neuropeptide with anti-stress-like activity

G. Perrault, D. Sanger, G. Griebel, 1999, Brain Research.

Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem.

G. Perrault, D. Sanger, E. Morel, 1992, The Journal of pharmacology and experimental therapeutics.

Nicotine-Associated Cues Maintain Nicotine-Seeking Behavior in Rats Several Weeks after Nicotine Withdrawal: Reversal by the Cannabinoid (CB1) Receptor Antagonist, Rimonabant (SR141716)

G. Perrault, G. Griebel, P. Soubrié, 2005, Neuropsychopharmacology.

New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (ω) receptor subtypes

G. Perrault, D. Sanger, H. Schoemaker, 1999, Psychopharmacology.

Further evidence for differences between non-selective and BZ-1 (ω1) Selective, benzodiazepine receptor ligands in murine models of “state” and “trait” Anxiety

G. Perrault, D. Sanger, G. Griebel, 1996, Neuropharmacology.

In vivo interaction of zolpidem with central benzodiazepine (BZD) binding sites (as labeled by [3H]Ro 15-1788) in the mouse brain. Preferential affinity of zolpidem for the omega 1 (BZD1) subtype.

G. Perrault, B. Scatton, A. Dubois, 1988, The Journal of pharmacology and experimental therapeutics.

The effects of compounds varying in selectivity as 5-HT1A receptor antagonists in three rat models of anxiety

G. Perrault, D. Sanger, G. Griebel, 2000, Neuropharmacology.

Decreased locomotor activity after microinjection of dopamine D2/D3 receptor agonists and antagonists into lobule 9 10 of the cerebellum: A D3 receptor mediated effect?

G. Perrault, D. Sanger, D. Boulay, 2000, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

CCK receptor antagonists in animal models of anxiety: comparison between exploration tests, conflict procedures and a model based on defensive behaviours

G. Perrault, D. Sanger, G. Griebel, 1997, Behavioural pharmacology.

SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit

R. Depoortère, G. Perrault, G. Griebel, 2005, Psychopharmacology.

Risk Assessment Behaviour: Evaluation of Utility in the Study of 5-HT-Related Drugs in the Rat Elevated Plus-Maze Test

G. Perrault, D. Sanger, G. Griebel, 1997, Pharmacology Biochemistry and Behavior.

Activity of litoxetine and other serotonin uptake inhibitors in the tail suspension test in mice

G. Perrault, D. Sanger, E. Morel, 1992, Pharmacology Biochemistry and Behavior.

Behavioural profiles in the mouse defence test battery suggest anxiolytic potential of 5-HT1A receptor antagonists

G. Perrault, D. Sanger, G. Griebel, 1999, Psychopharmacology.

Genetic differences in the mouse defense test battery

G. Perrault, D. Sanger, G. Griebel, 1997 .

Effects of dihydropyridine Ca2+ channel blockers on the discriminative stimulus and the motor impairing effects of (+/-)-Bay K 8644.

G. Perrault, D. Sanger, C. Cohen, 1997, European journal of pharmacology.

Assessment of the antidepressant-like effects of L-type voltage-dependent channel modulators

G. Perrault, C. Cohen, D J Sanger, 1997, Behavioural pharmacology.

Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents

G. Perrault, D. Sanger, G. Griebel, 1998, Journal of psychopharmacology.

A Comparative Study of the Effects of Selective and Non-Selective 5-HT2 Receptor Subtype Antagonists in Rat and Mouse Models of Anxiety

G. Perrault, D. Sanger, G. Griebel, 1997, Neuropharmacology.

The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (ω1) selective, benzodiazepine receptor ligands

G. Perrault, D. Sanger, G. Griebel, 1996, Psychopharmacology.

SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats

R. Depoortère, G. Perrault, G. Griebel, 2004, Neuropharmacology.

SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. II: Behavioral Profile Predictive of an Atypical Antipsychotic Activity

R. Depoortère, G. Perrault, J. Simiand, 2003, Neuropsychopharmacology.

Behavioral Effects of Acute and Chronic Fluoxetine in Wistar–Kyoto Rats

G. Perrault, D. Sanger, G. Griebel, 1999, Physiology & Behavior.

Prepulse inhibition of the startle reflex in rats: effects of compounds acting at various sites on the NMDA receptor complex.

R. Depoortère, G. Perrault, D. Sanger, 1999, Behavioural pharmacology.

Evidence for a role for dopamine D3 receptors in the effects of dopamine agonists on operant behaviour in rats.

R. Depoortère, G. Perrault, D. Sanger, 1996, Behavioural pharmacology.

Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine

R. Depoortère, G. Perrault, D. Sanger, 1996, Psychopharmacology.

Further Evidence for Differences Between Non-selective and BZ-1 ( o 1 ) Selective , Benzodiazepine Receptor Ligands in Murine Models of “ State ” and “ Trait ”

G. Perrault, Anxiety G. Griebel, 1997 .

Behavioural Pharmacology of Dopamine D2 and D3 Receptors: Use of the Knock-out Mice Approach

R. Depoortère, G. Perrault, D. Sanger, 2002 .

Differences in Anxiolytic-Like Profile of Two Novel Nonbenzodiazepine BZ (ϖ) Receptor Agonists on Defensive Behaviors of Mice

G. Perrault, D. Sanger, G. Griebel, 1999, Pharmacology Biochemistry and Behavior.

Amisulpride: from animal pharmacology to therapeutic action

G. Perrault, D. Sanger, H. Schoemaker, 1997, International clinical psychopharmacology.

[Contribution of zolpidem in the management of sleep disorders].

G. Perrault, P. Robert, J. Lavoisy, 1992, L'Encephale.

Study of the modulatory activity of bz (ω) receptor ligands on defensive behaviors in mice: Evaluation of the importance of intrinsic efficacy and receptor subtype selectivity

G. Perrault, D. Sanger, G. Griebel, 1999, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Ifenprodil and Eliprodil: Neuroprotective NMDA Receptor Antagonists and Calcium Channel Blockers

G. Perrault, D. Sanger, H. Schoemaker, 1997 .

SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors.

G. Perrault, H. Schoemaker, G. Griebel, 2001, Journal of Pharmacology and Experimental Therapeutics.

The anti‐ischaemic drug, eliprodil, blocks hyperactivity induced by intra‐accumbens injection of spermine

G. Perrault, D. Sanger, E. Audi, 1995, Behavioural pharmacology.

Protracted treatment with diazepam reduces benzodiazepine1 receptor-mediated potentiation of gamma-aminobutyric acid-induced currents in dissociated rat hippocampal neurons.

G. Perrault, B. Scatton, P. Granger, 1996, The Journal of pharmacology and experimental therapeutics.